Scarica l'app Stockscreener
34.77
1.40%
0.48
Dopo l'orario di chiusura:
34.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$34.29
Aprire:
$34.08
Volume 24 ore:
2.73M
Relative Volume:
1.28
Capitalizzazione di mercato:
$9.93B
Reddito:
$2.01B
Utile/perdita netta:
$349.99M
Rapporto P/E:
122.73
EPS:
0.2833
Flusso di cassa netto:
$166.29M
1 W Prestazione:
+21.02%
1M Prestazione:
+30.42%
6M Prestazione:
+58.77%
1 anno Prestazione:
+65.57%
Intervallo 1D:
$34.08
$35.15
Intervallo di 1 settimana:
$31.18
$35.15
Portata 52W:
$19.20
$35.15
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis (NASDAQ:EXEL) Sets New 52-Week HighTime to Buy? - MarketBeat
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now - Yahoo Canada Finance
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain? - Yahoo Finance
Capital Management Corp VA Increases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis's SWOT analysis: oncology leader's stock poised for growth - Investing.com
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook - MSN
3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool
New York State Teachers Retirement System Raises Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis cso sells stock worth $36,486 By Investing.com - Investing.com Australia
Dana Aftab Sells 1,162 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock - MarketBeat
Exelixis cso sells stock worth $36,486 - Investing.com
Exelixis (NASDAQ:EXEL) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Trend Tracker for (EXEL) - Stock Traders Daily
Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Exelixis price target raised to $38 from $33 at Truist - MSN
Stephens Investment Management Group LLC Has $98.78 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Call Transcript - Insider Monkey
Exelixis stock hits 52-week high at $31.3 amid robust growth - Investing.com Australia
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance - Investing.com
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance By Investing.com - Investing.com UK
Exelixis price target raised to $36 from $33 at Piper Sandler - Yahoo Finance
DekaBank Deutsche Girozentrale Acquires 30,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Exelixis EVP Jeffrey Hessekiel sells $709,750 in stock - Investing.com
Exelixis stock hits 52-week high at $31.3 amid robust growth By Investing.com - Investing.com South Africa
Royal Bank of Canada Reiterates Outperform Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Exelixis shares target lifted, retains equal weight on strong Q3 results - Investing.com
Exelixis (NASDAQ:EXEL) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Stephens Boosts Exelixis (NASDAQ:EXEL) Price Target to $29.00 - MarketBeat
Piper Sandler boosts Exelixis stock target on earnings beat and optimistic revenue outlook - Investing.com UK
FY2024 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock sees upside with cabozantinib’s patent extension and label expansion - Investing.com UK
Exelixis Reports Strong Q3 2024 Earnings and Pipeline Expansion - TipRanks
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Exelixis Earnings: Raising Valuation on Improved Outlook Thanks to Pipeline Candidate Zanzalintinib - Morningstar
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
No-Moat Exelixis Focuses on Developing Pipeline to Offset Future Generic Entry for Cabozantinib - Morningstar
Exelixis: Q3 Earnings Snapshot - The Advocate
Exelixis (EXEL) Q3 2024 Earnings Call Transcript - Yahoo! Voices
Exelixis Inc (EXEL) Q3 2024 Earnings: EPS of $0.40 Beats Estimat - GuruFocus.com
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
China Universal Asset Management Co. Ltd. Buys 20,641 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Q4 Earnings Estimate for Exelixis Issued By Leerink Partnrs - MarketBeat
Assenagon Asset Management S.A. Sells 588,870 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):